Allied Market Research
Loading...
Cart
0
PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, T&C*

New
New Allied Market Research

Breast Cancer Liquid Biopsy Market by Product & Service (Reagent Kits, Instruments, and Services), Circulating Biomarker (Circulating Tumor Cells, Extracellular Vesicles, and Circulating Tumor DNA), and Application (Diagnostics, Prognostics, and Risk Assessment): Global Opportunity Analysis and Industry Forecast, 2019–2027

A07618
Pages: 305
Feb 2021 | 1110 Views
 
Author(s) : Sagar Mukhekar, Sushant Terdale , Onkar Sumant
Tables: 187
Charts: 51
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Breast Cancer Liquid Biopsy Market

Request Now !

The global breast cancer liquid biopsy market size was valued at $87,641 thousand in 2019, and is projected to reach $357,051 thousand by 2027, registering a CAGR of 19.2% from 2019 to 2027.

The breast cancer liquid biopsy is a noninvasive alternative technique that makes use of blood as a sample and is chosen more than surgical tissue biopsy. There are various biomarkers that are used as a tool for detection of breast cancer such as circulating tumor cells (CTC), extracellular vesicles, and circulating tumor DNA. Breast cancer liquid biopsy aids to monitor progression of breast cancer disease based on heterogeneity of tumor cells in advanced stages of breast cancer. Moreover, breast cancer liquid biopsy test detects epidermal growth factor receptor (EGFR) gene mutations that support clinicians to choose the right breast cancer treatment at the right time.

Breast-Cancer-Liquid-Biopsy-Market,-2019-2027

Get more information on this report : Request Sample Pages

Rise in prevalence of breast cancer, increase in demand for non-invasive breast cancer treatment, technological advancements in breast cancer liquid biopsy, availability of funding for liquid biopsy R&D, and increase in breast cancer liquid biopsy reagent approvals are the major factors that drive growth of the breast cancer liquid biopsy market. In addition, increase in patient awareness toward breast cancer treatment, advantages of breast cancer liquid biopsy tests over traditional tests, rise in adoption of liquid biopsy tests, surge in pre-screening programs for breast cancer detection, easy accessibility and high adoption of polymerase chain reaction (PCR) and next-generation sequencing (NGS) among healthcare professionals, and surge in demand for breast cancer liquid biopsy reagent kits are some other factors that contribute toward growth of the market. However, limitations associated with liquid biopsy testing and lack of access and awareness regarding breast cancer liquid biopsy in underdeveloped countries are expected to hinder growth of the market.  

The World Health Organization (WHO) on January 30, 2020 declared COVID-19 outbreak a public health emergency of international concern. COVID-19 has affected around 210 countries across the globe. The breast cancer liquid biopsy manufacturing and distributing companies have been affected by COVID-19 to a limited extent, owing to shutdowns in various COVID-19 affected countries and rise in number of healthcare workers falling ill in the wake of the COVID-19 pandemic, leading to short supply.

Breast Cancer Liquid Biopsy Market Segmentation  

The global breast cancer liquid biopsy market is segmented on the basis of product & service, circulating biomarker, application, and region. By product & service, the market is categorized into reagent kits, instruments, and services. By circulating biomarker, it is segregated into circulating tumor cells, extracellular vesicles, and circulating tumor DNA. Depending on application, it is classified into diagnostics, prognostics, and risk assessment. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Breast Cancer Liquid Biopsy Market
By Product & Service

Your browser does not support the canvas element.

Reagent Kit segment holds a dominant position in 2019 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Segment review 

Presently, on the basis of product & service, the reagent kits is the major revenue contributor, and is projected to grow significantly during the forecast period. Increase in number of breast cancer liquid biopsy test procedures, surge in demand for reagent kits, increase in breast cancer liquid biopsy reagent kit approvals, and advent of novel liquid biopsy reagents that execute circulating biomarker analysis and target enrichment are the key factors that boost growth of the segment.

Depending on application, the diagnostics segment is the major shareholder in the global breast cancer liquid biopsy market, owing to technological advancements in liquid biopsy systems, and increase in patient awareness toward safe and non-invasive liquid biopsy testing procedures. Moreover, rise in trend of developing personalized therapeutics and increase in number of patients suffering from breast cancer across the globe are other factors that contribute toward growth of the market.

Breast Cancer Liquid Biopsy Market
By Application

Your browser does not support the canvas element.

Diagnostics segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Snapshot of Asia-Pacific breast cancer liquid biopsy market  

Asia-Pacific presents lucrative opportunities for key players operating in the breast cancer liquid biopsy market, owing to increase in number of patients suffering from breast cancer, increase in public awareness toward breast cancer liquid biopsy procedures, development of the R&D sector; rise in healthcare reforms; and increase in adoption of breast cancer liquid biopsy. Moreover, increase in demand for breast cancer liquid biopsy reagent kits, and rise in preference for noninvasive test procedures contribute toward growth of the market. Furthermore, surge in focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture high market share is expected to drive growth of the breast cancer liquid biopsy market in the region.

The key players profiled in this report include Biocept, Inc., F. Hoffmann-La Roche Ltd. (Foundation Medicine, Inc.), Fluxion Biosciences, Inc., Menarini Group (Menarini Silicon Biosystems, Inc.), Myriad Genetics, Inc., NeoGenomics Laboratories, Inc., Qiagen N.V., Sysmex Corporation, and Thermo Fisher Scientific Inc.

Breast Cancer Liquid Biopsy Market
By Region

2027
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 20.1% during 2019-2027.

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the breast cancer liquid biopsy market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers breast cancer liquid biopsy market analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis of four regions is provided to determine the prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global breast cancer liquid biopsy market growth.

Key Market Segments

By Product & Service

  • Reagent Kits
  • Instruments
  • Services

By Circulating Biomarker

  • Circulating Tumor Cells
  • Extracellular Vesicles
  • Circulating Tumor DNA

By Application

  • Diagnostics
  • Prognostics
  • Risk assessment

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China 
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East
    • Africa
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five force analysis
3.4.Top player positioning, 2019

3.4.1.Breast Cancer
3.4.2.All Cancer Types

3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in demand for safe and non-invasive procedures
3.5.1.2.Surge in global prevalence rate of breast cancer
3.5.1.3.Advantages of breast cancer liquid biopsy tests over traditional tests

3.5.2.Restraint

3.5.2.1.Lack of access and awareness in underdeveloped countries

3.5.3.Opportunity

3.5.3.1.High growth potential in emerging markets

3.5.4.Impact analysis

3.6.Pricing analysis
3.7.Reimbursement scenario
3.8.Clinical validations
3.9.Regulatory landscape
3.10.List of approved liquid biopsy tests

CHAPTER 4:BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE

4.1.Overview

4.1.1.Market size and forecast

4.2.Reagent kits

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Instruments

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country

4.4.Services

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country

CHAPTER 5:BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER

5.1.Overview

5.1.1.Market size and forecast

5.2.Circulating tumor cells

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Extracellular vesicles

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Circulating tumor DNA

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

CHAPTER 6:BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION

6.1.Overview

6.1.1.Market size and forecast

6.2.Diagnostics

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Prognostics

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.4.Risk assessment

6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country

CHAPTER 7:BREAST CANCER LIQUID BIOPSY MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country

7.2.2.1.U.S.

7.2.2.1.1.U.S. breast cancer liquid biopsy market, by product & service
7.2.2.1.2.U.S. breast cancer liquid biopsy market, by circulating biomarker
7.2.2.1.3.U.S. breast cancer liquid biopsy market, by application

7.2.2.2.Canada

7.2.2.2.1.Canada breast cancer liquid biopsy market, by product & service
7.2.2.2.2.Canada breast cancer liquid biopsy market, by circulating biomarker
7.2.2.2.3.Canada breast cancer liquid biopsy market, by application

7.2.2.3.Mexico

7.2.2.3.1.Mexico breast cancer liquid biopsy market, by product & service
7.2.2.3.2.Mexico breast cancer liquid biopsy market, by circulating biomarker
7.2.2.3.3.Mexico breast cancer liquid biopsy market, by application

7.2.3.North America market size and forecast, by product & service
7.2.4.North America market size and forecast, by circulating biomarker
7.2.5.North America market size and forecast, by application

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country

7.3.2.1.Germany

7.3.2.1.1.Germany breast cancer liquid biopsy market, by product & service
7.3.2.1.2.Germany breast cancer liquid biopsy market, by circulating biomarker
7.3.2.1.3.Germany breast cancer liquid biopsy market, by application

7.3.2.2.France

7.3.2.2.1.France breast cancer liquid biopsy market, by product & service
7.3.2.2.2.France breast cancer liquid biopsy market, by circulating biomarker
7.3.2.2.3.France breast cancer liquid biopsy market, by application

7.3.2.3.UK

7.3.2.3.1.UK breast cancer liquid biopsy market, by product & service
7.3.2.3.2.UK breast cancer liquid biopsy market, by circulating biomarker
7.3.2.3.3.UK breast cancer liquid biopsy market, by application

7.3.2.4.Italy

7.3.2.4.1.Italy breast cancer liquid biopsy market, by product & service
7.3.2.4.2.Italy breast cancer liquid biopsy market, by circulating biomarker
7.3.2.4.3.Italy breast cancer liquid biopsy market, by application

7.3.2.5.Spain

7.3.2.5.1.Spain breast cancer liquid biopsy market, by product & service
7.3.2.5.2.Spain breast cancer liquid biopsy market, by circulating biomarker
7.3.2.5.3.Spain breast cancer liquid biopsy market, by application

7.3.2.6.Rest of Europe

7.3.2.6.1.Rest of Europe breast cancer liquid biopsy market, by product & service
7.3.2.6.2.Rest of Europe breast cancer liquid biopsy market, by circulating biomarker
7.3.2.6.3.Rest of Europe breast cancer liquid biopsy market, by application

7.3.3.Europe market size and forecast, by product & service
7.3.4.Europe market size and forecast, by circulating biomarker
7.3.5.Europe market size and forecast, by application

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country

7.4.2.1.Japan

7.4.2.1.1.Japan breast cancer liquid biopsy market, by product & service
7.4.2.1.2.Japan breast cancer liquid biopsy market, by circulating biomarker
7.4.2.1.3.Japan breast cancer liquid biopsy market, by application

7.4.2.2.China

7.4.2.2.1.China breast cancer liquid biopsy market, by product & service
7.4.2.2.2.China breast cancer liquid biopsy market, by circulating biomarker
7.4.2.2.3.China breast cancer liquid biopsy market, by application

7.4.2.3.India

7.4.2.3.1.India breast cancer liquid biopsy market, by product & service
7.4.2.3.2.India breast cancer liquid biopsy market, by circulating biomarker
7.4.2.3.3.India breast cancer liquid biopsy market, by application

7.4.2.4.Rest of Asia-Pacific

7.4.2.4.1.Rest of Asia-Pacific breast cancer liquid biopsy market, by product & service
7.4.2.4.2.Rest of Asia-Pacific breast cancer liquid biopsy market, by circulating biomarker
7.4.2.4.3.Rest of Asia-Pacific breast cancer liquid biopsy market, by application

7.4.3.Asia-Pacific market size and forecast, by product & service
7.4.4.Asia-Pacific market size and forecast, by circulating biomarker
7.4.5.Asia-Pacific market size and forecast, by application

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country

7.5.2.1.Latin America

7.5.2.1.1.Latin America breast cancer liquid biopsy market, by product & service
7.5.2.1.2.Latin America breast cancer liquid biopsy market, by circulating biomarker
7.5.2.1.3.Latin America breast cancer liquid biopsy market, by application

7.5.2.2.Middle East

7.5.2.2.1.Middle East breast cancer liquid biopsy market, by product & service
7.5.2.2.2.Middle East breast cancer liquid biopsy market, by circulating biomarker
7.5.2.2.3.Middle East breast cancer liquid biopsy market, by application

7.5.2.3.Africa

7.5.2.3.1.Africa breast cancer liquid biopsy market, by product & service
7.5.2.3.2.Africa breast cancer liquid biopsy market, by circulating biomarker
7.5.2.3.3.Africa breast cancer liquid biopsy market, by application

7.5.3.LAMEA market size and forecast, by product & service
7.5.4.LAMEA market size and forecast, by circulating biomarker
7.5.5.LAMEA market size and forecast, by application

CHAPTER 8:COMPANY PROFILES

8.1.BIOCEPT INC.

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments

8.2.F. HOFFMANN-LA ROCHE LTD. (FOUNDATION MEDICINE, INC.)

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments

8.3.FLUXION BIOSCIENCES, INC.

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio

8.4.MENARINI GROUP (MENARINI SILICON BIOSYSTEMS, INC.)

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Key strategic moves and developments

8.5.MYRIAD GENETICS, INC.

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance

8.6.NEOGENOMICS LABORATORIES, INC.

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments

8.7.QIAGEN N.V.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments

8.8.SYSMEX CORPORATION

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance

8.9.THERMO FISHER SCIENTIFIC, INC.

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance

8.10.GUARDANT HEALTH, INC.

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 ($THOUSAND)
TABLE 02.BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 (UNITS)
TABLE 03.REAGENT KITS BREAST CANCER LIQUID BIOPSY MARKET, BY REGION, 2019–2027 ($THOUSAND)
TABLE 04.REAGENT KITS BREAST CANCER LIQUID BIOPSY MARKET, BY REGION, 2019–2027 (UNITS)
TABLE 05.INSTRUMENTS BREAST CANCER LIQUID BIOPSY MARKET, BY REGION, 2019–2027 ($THOUSAND)
TABLE 06.INSTRUMENTS BREAST CANCER LIQUID BIOPSY MARKET, BY REGION, 2019–2027 (UNITS)
TABLE 07.SERVICE BREAST CANCER LIQUID BIOPSY MARKET, BY REGION, 2019–2027 ($THOUSAND)
TABLE 08.SERVICE BREAST CANCER LIQUID BIOPSY MARKET, BY REGION, 2019–2027 (UNITS)
TABLE 09.BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 ($THOUSAND)
TABLE 10.BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 (UNITS)
TABLE 11.CIRCULATING TUMOR CELLS BREAST CANCER LIQUID BIOPSY MARKET, BY REGION, 2019–2027 ($THOUSAND)
TABLE 12.CIRCULATING TUMOR CELLS BREAST CANCER LIQUID BIOPSY MARKET, BY REGION, 2019–2027 (UNITS)
TABLE 13.EXTRACELLULAR VESICLES BREAST CANCER LIQUID BIOPSY MARKET, BY REGION, 2019–2027 ($THOUSAND)
TABLE 14.EXTRACELLULAR VESICLES BREAST CANCER LIQUID BIOPSY MARKET, BY REGION, 2019–2027 (UNITS)
TABLE 15.CIRCULATING TUMOR DNA BREAST CANCER LIQUID BIOPSY MARKET, BY REGION, 2019–2027 ($THOUSAND)
TABLE 16.CIRCULATING TUMOR DNA BREAST CANCER LIQUID BIOPSY MARKET, BY REGION, 2019–2027 (UNITS)
TABLE 17.BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 ($THOUSAND)
TABLE 18.BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 (UNITS)
TABLE 19.DIAGNOSTICS BREAST CANCER LIQUID BIOPSY MARKET, BY REGION, 2019–2027 ($THOUSAND)
TABLE 20.DIAGNOSTICS BREAST CANCER LIQUID BIOPSY MARKET, BY REGION, 2019–2027 (UNITS)
TABLE 21.PROGNOSTICS BREAST CANCER LIQUID BIOPSY MARKET, BY REGION, 2019–2027 ($THOUSAND)
TABLE 22.PROGNOSTICS BREAST CANCER LIQUID BIOPSY MARKET, BY REGION, 2019–2027 (UNITS)
TABLE 23.RISK ASSESSMENT BREAST CANCER LIQUID BIOPSY MARKET, BY REGION, 2019–2027 ($THOUSAND)
TABLE 24.RISK ASSESSMENT BREAST CANCER LIQUID BIOPSY MARKET, BY REGION, 2019–2027 (UNITS)
TABLE 25.BREAST CANCER LIQUID BIOPSY MARKET, BY REGION, 2019–2027 ($THOUSAND)
TABLE 26.BREAST CANCER LIQUID BIOPSY MARKET, BY REGION, 2019–2027 (UNITS)
TABLE 27.NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET, BY COUNTRY, 2019–2027 ($THOUSAND)
TABLE 28.NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET, BY COUNTRY, 2019–2027 (UNITS)
TABLE 29.U.S. BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 ($THOUSAND)
TABLE 30.U.S. BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 (UNITS)
TABLE 31.U.S. BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 ($THOUSAND)
TABLE 32.U.S. BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 (UNITS)
TABLE 33.U.S. BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 ($THOUSAND)
TABLE 34.U.S. BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 (UNITS)
TABLE 35.CANADA BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 ($THOUSAND)
TABLE 36.CANADA BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 (UNITS)
TABLE 37.CANADA BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 ($THOUSAND)
TABLE 38.CANADA BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 (UNITS)
TABLE 39.CANADA BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 ($THOUSAND)
TABLE 40.CANADA BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 (UNITS)
TABLE 41.MEXICO BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 ($THOUSAND)
TABLE 42.MEXICO BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 (UNITS)
TABLE 43.MEXICO BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 ($THOUSAND)
TABLE 44.MEXICO BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 (UNITS)
TABLE 45.MEXICO BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 ($THOUSAND)
TABLE 46.MEXICO BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 (UNITS)
TABLE 47.NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 ($THOUSAND)
TABLE 48.NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 (UNITS)
TABLE 49.NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 ($THOUSAND)
TABLE 50.NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 (UNITS)
TABLE 51.NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 ($THOUSAND)
TABLE 52.NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 (UNITS)
TABLE 53.EUROPE BREAST CANCER LIQUID BIOPSY MARKET, BY COUNTRY, 2019–2027 ($THOUSAND)
TABLE 54.EUROPE BREAST CANCER LIQUID BIOPSY MARKET, BY COUNTRY, 2019–2027 (UNITS)
TABLE 55.GERMANY BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 ($THOUSAND)
TABLE 56.GERMANY BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 (UNITS)
TABLE 57.GERMANY BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 ($THOUSAND)
TABLE 58.GERMANY BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 (UNITS)
TABLE 59.GERMANY BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 ($THOUSAND)
TABLE 60.GERMANY BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 (UNITS)
TABLE 61.FRANCE BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 ($THOUSAND)
TABLE 62.FRANCE BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 (UNITS)
TABLE 63.FRANCE BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 ($THOUSAND)
TABLE 64.FRANCE BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 (UNITS)
TABLE 65.FRANCE BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 ($THOUSAND)
TABLE 66.FRANCE BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 (UNITS)
TABLE 67.UK BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 ($THOUSAND)
TABLE 68.UK BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 (UNITS)
TABLE 69.UK BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 ($THOUSAND)
TABLE 70.UK BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 (UNITS)
TABLE 71.UK BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 ($THOUSAND)
TABLE 72.UK BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 (UNITS)
TABLE 73.ITALY BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 ($THOUSAND)
TABLE 74.ITALY BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 (UNITS)
TABLE 75.ITALY BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 ($THOUSAND)
TABLE 76.ITALY BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 (UNITS)
TABLE 77.ITALY BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 ($THOUSAND)
TABLE 78.ITALY BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 (UNITS)
TABLE 79.SPAIN BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 ($THOUSAND)
TABLE 80.SPAIN BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 (UNITS)
TABLE 81.SPAIN BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 ($THOUSAND)
TABLE 82.SPAIN BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 (UNITS)
TABLE 83.SPAIN BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 ($THOUSAND)
TABLE 84.SPAIN BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 (UNITS)
TABLE 85.REST OF EUROPE BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 ($THOUSAND)
TABLE 86.REST OF EUROPE BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 (UNITS)
TABLE 87.REST OF EUROPE BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 ($THOUSAND)
TABLE 88.REST OF EUROPE BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 (UNITS)
TABLE 89.REST OF EUROPE BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 ($THOUSAND)
TABLE 90.REST OF EUROPE BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 (UNITS)
TABLE 91.EUROPE BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 ($THOUSAND)
TABLE 92.EUROPE BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 (UNITS)
TABLE 93.EUROPE BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 ($THOUSAND)
TABLE 94.EUROPE BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 (UNITS)
TABLE 95.EUROPE BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 ($THOUSAND)
TABLE 96.EUROPE BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 (UNITS)
TABLE 97.ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET, BY COUNTRY, 2019–2027 ($THOUSAND)
TABLE 98.ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET, BY COUNTRY, 2019–2027 (UNITS)
TABLE 99.JAPAN BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 ($THOUSAND)
TABLE 100.JAPAN BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 (UNITS)
TABLE 101.JAPAN BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 ($THOUSAND)
TABLE 102.JAPAN BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 (UNITS)
TABLE 103.JAPAN BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 ($THOUSAND)
TABLE 104.JAPAN BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 (UNITS)
TABLE 105.CHINA BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 ($THOUSAND)
TABLE 106.CHINA BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 (UNITS)
TABLE 107.CHINA BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 ($THOUSAND)
TABLE 108.CHINA BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 (UNITS)
TABLE 109.CHINA BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 ($THOUSAND)
TABLE 110.CHINA BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 (UNITS)
TABLE 111.INDIA BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 ($THOUSAND)
TABLE 112.INDIA BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 (UNITS)
TABLE 113.INDIA BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 ($THOUSAND)
TABLE 114.INDIA BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 (UNITS)
TABLE 115.INDIA BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 ($THOUSAND)
TABLE 116.INDIA BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 (UNITS)
TABLE 117.REST OF ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 ($THOUSAND)
TABLE 118.REST OF ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 (UNITS)
TABLE 119.REST OF ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 ($THOUSAND)
TABLE 120.REST OF ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 (UNITS)
TABLE 121.REST OF ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 ($THOUSAND)
TABLE 122.REST OF ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 (UNITS)
TABLE 123.ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 ($THOUSAND)
TABLE 124.ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 (UNITS)
TABLE 125.ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 ($THOUSAND)
TABLE 126.ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 (UNITS)
TABLE 127.ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 ($THOUSAND)
TABLE 128.ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 (UNITS)
TABLE 129.LAMEA BREAST CANCER LIQUID BIOPSY MARKET, BY COUNTRY, 2019–2027 ($THOUSAND)
TABLE 130.LAMEA BREAST CANCER LIQUID BIOPSY MARKET, BY COUNTRY, 2019–2027 (UNITS)
TABLE 131.LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 ($THOUSAND)
TABLE 132.LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 (UNITS)
TABLE 133.LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 ($THOUSAND)
TABLE 134.LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 (UNITS)
TABLE 135.LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 ($THOUSAND)
TABLE 136.LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 (UNITS)
TABLE 137.MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 ($THOUSAND)
TABLE 138.MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 (UNITS)
TABLE 139.MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 ($THOUSAND)
TABLE 140.MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 (UNITS)
TABLE 141.MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 ($THOUSAND)
TABLE 142.MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 (UNITS)
TABLE 143.AFRICA BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 ($THOUSAND)
TABLE 144.AFRICA BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 (UNITS)
TABLE 145.AFRICA BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 ($THOUSAND)
TABLE 146.AFRICA BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 (UNITS)
TABLE 147.AFRICA BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 ($THOUSAND)
TABLE 148.AFRICA BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 (UNITS)
TABLE 149.LAMEA BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 ($THOUSAND)
TABLE 150.LAMEA BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2027 (UNITS)
TABLE 151.LAMEA BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 ($THOUSAND)
TABLE 152.LAMEA BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2019–2027 (UNITS)
TABLE 153.LAMEA BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 ($THOUSAND)
TABLE 154.LAMEA BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2027 (UNITS)
TABLE 155.BIOCEPT: COMPANY SNAPSHOT
TABLE 156.BIOCEPT: PRODUCT PORTFOLIO
TABLE 157.BIOCEPT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 158.ROCHE: COMPANY SNAPSHOT
TABLE 159.ROCHE: OPERATING SEGMENT
TABLE 160.ROCHE: PRODUCT PORTFOLIO
TABLE 161.ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 162.FLUXION: COMPANY SNAPSHOT
TABLE 163.FLUXION: PRODUCT PORTFOLIO
TABLE 164.MENARINI: COMPANY SNAPSHOT
TABLE 165.MENARINI: PRODUCT PORTFOLIO
TABLE 166.MENARINI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 167.MYRIAD: COMPANY SNAPSHOT
TABLE 168.MYRIAD: OPERATING SEGMENTS
TABLE 169.MYRIAD: PRODUCT PORTFOLIO
TABLE 170.NEOGENOMICS: COMPANY SNAPSHOT
TABLE 171.NEOGENOMICS: OPERATING SEGMENT
TABLE 172.NEOGENOMICS: PRODUCT PORTFOLIO
TABLE 173.NEOGENOMICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 174.QIAGEN: COMPANY SNAPSHOT
TABLE 175.QIAGEN: OPERATING SEGMENT
TABLE 176.QIAGEN: PRODUCT PORTFOLIO
TABLE 177.QIAGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 178.SYSMEX: COMPANY SNAPSHOT
TABLE 179.SYSMEX: OERATING SEGMENT
TABLE 180.SYSMEX.: PRODUCT PORTFOLIO
TABLE 181.THERMO FISHER: COMPANY SNAPSHOT
TABLE 182.THERMO FISHER.: OPERATING SEGMENT
TABLE 183.THERMO FISHER.: PRODUCT PORTFOLIO
TABLE 184.GUARDANT: COMPANY SNAPSHOT
TABLE 185.GUARDANT: OPERATING SEGMENT
TABLE 186.GUARDANT: PRODUCT PORTFOLIO
TABLE 187.GUARDANT: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 01.GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017–2019
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017–2019
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017–2019
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.HIGH THREAT OF SUBSTITUTES
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2019
FIGURE 12.TOP PLAYER POSITIONING, 2019
FIGURE 13.IMPACT ANALYSIS
FIGURE 14.COMPARATIVE ANALYSIS OF REAGENT KITS BREAST CANCER LIQUID BIOPSY MARKET, BY COUNTRY, 2019 & 2027 ($THOUSAND)
FIGURE 15.COMPARATIVE ANALYSIS OF REAGENT KITS BREAST CANCER LIQUID BIOPSY MARKET, BY COUNTRY, 2019 & 2027 (UNITS)
FIGURE 16.COMPARATIVE ANALYSIS OF INSTRUMENTS BREAST CANCER LIQUID BIOPSY MARKET, BY COUNTRY,  2019 & 2027 ($THOUSAND)
FIGURE 17.COMPARATIVE ANALYSIS OF INSTRUMENTS BREAST CANCER LIQUID BIOPSY MARKET, BY COUNTRY,  2019 & 2027 (UNITS)
FIGURE 18.COMPARATIVE ANALYSIS OF SERVICES BREAST CANCER LIQUID BIOPSY MARKET, BY COUNTRY, 2019 & 2027 ($THOUSAND)
FIGURE 19.COMPARATIVE ANALYSIS OF SERVICES BREAST CANCER LIQUID BIOPSY MARKET, BY COUNTRY, 2019 & 2027 (UNITS)
FIGURE 20.COMPARATIVE ANALYSIS OF CIRCULATING TUMOR CELLS BREAST CANCER LIQUID BIOPSY MARKET,  BY COUNTRY, 2019 & 2027 ($THOUSAND)
FIGURE 21.COMPARATIVE ANALYSIS OF CIRCULATING TUMOR CELLS BREAST CANCER LIQUID BIOPSY MARKET,  BY COUNTRY, 2019 & 2027 (UNITS)
FIGURE 22.COMPARATIVE ANALYSIS OF EXTRACELLULAR VESICLES BREAST CANCER LIQUID BIOPSY MARKET, BY COUNTRY, 2019 & 2027 ($THOUSAND)
FIGURE 23.COMPARATIVE ANALYSIS OF EXTRACELLULAR VESICLES BREAST CANCER LIQUID BIOPSY MARKET, BY COUNTRY, 2019 & 2027 (UNITS)
FIGURE 24.COMPARATIVE ANALYSIS OF CIRCULATING TUMOR DNA BREAST CANCER LIQUID BIOPSY MARKET, BY COUNTRY, 2019 & 2027 ($THOUSAND)
FIGURE 25.COMPARATIVE ANALYSIS OF CIRCULATING TUMOR DNA BREAST CANCER LIQUID BIOPSY MARKET, BY COUNTRY, 2019 & 2027 (UNITS)
FIGURE 26.COMPARATIVE ANALYSIS OF DIAGNOSTICS BREAST CANCER LIQUID BIOPSY MARKET, BY COUNTRY, 2019 & 2027 ($THOUSAND)
FIGURE 27.COMPARATIVE ANALYSIS OF DIAGNOSTICS BREAST CANCER LIQUID BIOPSY MARKET, BY COUNTRY, 2019 & 2027 (UNITS)
FIGURE 28.COMPARATIVE ANALYSIS OF PROGNOSTICS BREAST CANCER LIQUID BIOPSY MARKET, BY COUNTRY,  2019 & 2027 ($THOUSAND)
FIGURE 29.COMPARATIVE ANALYSIS OF PROGNOSTICS BREAST CANCER LIQUID BIOPSY MARKET, BY COUNTRY,  2019 & 2027 (UNITS)
FIGURE 30.COMPARATIVE ANALYSIS OF RISK ASSESSMENT BREAST CANCER LIQUID BIOPSY MARKET, BY COUNTRY,  2019 & 2027 ($THOUSAND)
FIGURE 31.COMPARATIVE ANALYSIS OF RISK ASSESSMENT BREAST CANCER LIQUID BIOPSY MARKET, BY COUNTRY, 2019 & 2027 (UNITS)
FIGURE 32.BIOCEPT: NET SALES, 2017–2019 ($MILLION)
FIGURE 33.ROCHE: NET SALES, 2017–2019 ($MILLION)
FIGURE 34.ROCHE: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 35.ROCHE: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 36.MYRIAD: NET SALES, 2018-2020 ($MILLION)
FIGURE 37.MYRIAD: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 38.NEOGENOMICS: NET SALES, 2017–2019 ($MILLION)
FIGURE 39.NEOGENOMICS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 40.QIAGEN: NET SALES, 2017–2019 ($MILLION)
FIGURE 41.QIAGEN: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 42.QIAGEN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 43.SYSMEX: NET SALES, 2017–2019 ($MILLION)
FIGURE 44.SYSMEX: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 45.SYSMEX: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 46.THERMO FISHER: NET SALES, 2017–2019 ($MILLION)
FIGURE 47.THERMO FISHER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 48.THERMO FISHER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 49.GUARDANT: NET SALES, 2017–2019 ($MILLION)
FIGURE 50.GUARDANT: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 51.GUARDANT: REVENUE SHARE, BY REGION, 2019 (%)

 
 

Breast cancer liquid biopsy tests have gained popularity as a simple, efficient, non-invasive alternative to solid tissue biopsies for breast cancer treatment. Moreover, breast cancer liquid biopsy tests are used for diagnostic and molecular characterization of tumor fragments and agents released in blood of breast cancer patients.

Rise in prevalence of breast cancer, surge in demand for breast cancer liquid biopsy reagent kits, rise in R&D activities and product innovations, and surge in pre-screening programs for breast cancer detection are expected to drive growth of the breast cancer liquid biopsy market. Moreover, increase in awareness among the population regarding breast cancer, rise in adoption of liquid biopsy tests, and rise in need for prognostic and diagnostic tests propel the market growth. However, limitations associated with liquid biopsy testing and lack of access and awareness regarding breast cancer liquid biopsy in underdeveloped countries are expected to hinder growth of the market.

North America is expected to remain dominant during the forecast period, owing to increase in demand for breast cancer liquid biopsy, rise in prevalence of breast cancer, and presence of major key players along with R&D centers. Moreover, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to key players during the forecast period, owing to increase in patient awareness toward breast cancer treatment.
 

 
PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. Rise in prevalence of breast cancer, increase in preference for noninvasive procedures, technological advancements in breast cancer liquid biopsy instruments, advantages of over solid tumor biopsy, and increase in patient awareness toward minimally invasive breast cancer liquid biopsy procedures are the key factors that fuel growth of the breast cancer liquid biopsy market. In addition, rise in funding for breast liquid biopsy R&D, favorable initiatives undertaken by governments and global health organizations, and increase in breast cancer liquid biopsy reagents approvals are another factor that contributes toward the growth of the market

A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as India with a CAGR of 21.7%. This is due to increase in preference for noninvasive procedures, technological advancements to detect breast cancer at early stage, increase in government initiatives to surge awareness about genome-based diagnostic procedures, and high adoption of polymerase chain reaction (PCR) and next-generation sequencing (NGS) among healthcare professionals.

A. Top companies such as F. Hoffmann-La Roche Ltd. (Foundation Medicine, Inc.), Biocept Inc., Menarini Group (Menarini Silicon Biosystems, Inc.), Qiagen N.V., Myriad Genetics, Inc., and NeoGenomics Laboratories, Inc. held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.

A. Reagent kits segment is the most influencing segment owing to advent of novel liquid biopsy reagents that execute circulating biomarker analysis and target enrichment; increase in breast cancer liquid biopsy reagent kits approvals; and increase in funding for breast cancer liquid biopsy R&D are anticipated to drive the growth of the market. In addition, surge in demand for reagent kits, rise in number of breast cancer liquid biopsy test procedures, and increase in prevalence of breast cancer across the globe are other factors that contribute toward growth of the market.

A. The total market value of Breast Cancer Liquid Biopsy market is $87,640.8 thousand in 2019.

A. The forcast period for Breast Cancer Liquid Biopsy market is 2019 to 2027

A. The market value of Breast Cancer Liquid Biopsy market in 2020 is $83,468.5 thousand .

A. The base year is 2019 in Breast Cancer Liquid Biopsy market

A. Breast cancer liquid biopsy is a non-invasive blood test that detects tumor DNA fragments and circulating tumor cells (CTCs), which are released into the blood from primary tumors and metastatic sites

A. Breast cancer liquid biopsy provides a real-time method for treatment of breast cancer. It is used for collection & analysis of a blood sample taken from patients. It analyses the presence of tumor cell-derived biomarkers such as circulating tumor cells, extracellular vesicles, and circulating tumor DNA.

Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Breast Cancer Liquid Biopsy Market

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $9,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library. T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers